Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 15 (final count)
- Started
- Oct 26, 2021
- Main results expected
- Mar 2027
- Fully finished
- Mar 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL)
Measured over: up to 26 weeks
Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd)
Measured over: up to 26 weeks
Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis
Measured over: up to 26 weeks
Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysis
Measured over: up to 26 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04833894 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC